Bristol Myers Squibb Receives Approval for Abecma (idecabtagene vicleucel), the First CAR T Therapy Approved for the Treatment of Multiple Myeloma in Japan

On January 20, 2022

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home/biznews/public_html/wp-includes/functions.php on line 5219

Related Post

Taiwan’s Tech Titans Adopt World’s First NVIDIA Grace CPU-Powered System Designs

GE Healthcare update on iodinated contrast media

Tyson Foods Announces Quarterly Dividend